<- Go Home
OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Market Cap
$42.4M
Volume
102.6K
Cash and Equivalents
$70.3M
EBITDA
-$66.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$16.91
52 Week Low
$1.70
Dividend
N/A
Price / Book Value
0.64
Price / Earnings
-0.66
Price / Tangible Book Value
0.64
Enterprise Value
-$27.2M
Enterprise Value / EBITDA
0.41
Operating Income
-$66.7M
Return on Equity
207.36%
Return on Assets
-96.53
Cash and Short Term Investments
$70.3M
Debt
$687.0K
Equity
$66.4M
Revenue
N/A
Unlevered FCF
-$33.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium